Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Anushka Mukherjee

Is Bristol-Myers Stock Underperforming the S&P 500?

New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical giant focused on discovering, developing and delivering innovative medicines for serious diseases, with core areas including oncology, immunology, cardiovascular conditions and blood disorders. Bristol-Myers Squibb commands a powerful presence in oncology, led by blockbuster immuno-oncology therapies including Opdivo, Opdivo Qvantig, and Yervoy, among others.

With a market capitalization of around $100.3 billion, Bristol-Myers comfortably sits in the “large-cap” tier, a class that generally includes companies valued at $10 billion or more. Through a strong pipeline supported by global clinical research across severe and immune-mediated conditions, Bristol-Myers aims to continue delivering breakthrough medicines for patients with unmet needs. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.